Switzerland
· Delayed Price · Currency is CHF Xlife Sciences AG Company Description
Xlife Sciences AG focuses on the development and commercialization of technologies in the life sciences sector.
The company’s project consists of technology platforms that focuses on identifying new therapeutic approaches and biomarkers for common diseases based on human genetic data.
It also engages in developing mono-and bispecific anti-tumor antibodies for the treatment of life-threatening diseases; researching, developing, and manufacturing chemical and active pharmaceutical ingredients for human and veterinary medicines; and early identification kidney diseases.
Xlife Sciences AG also focuses on functional screening of antibodies by microfluidics-based technologies; and offers Neuromex, a screening instrument for the early-stage detection of neurodegenerative diseases.
Xlife Sciences AG was founded in 2019 and is based in Zurich, Switzerland.
| Country | Switzerland |
| Founded | 2019 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 17 |
| CEO | Oliver Baumann |
Contact Details
Address: Talacker 35 Zurich, 8001 Switzerland | |
| Phone | 41 44 385 84 60 |
| Website | xlifesciences.ch |
Stock Details
| Ticker Symbol | XLS |
| Exchange | SIX Swiss Exchange |
| Fiscal Year | January - December |
| Reporting Currency | CHF |
| ISIN Number | CH0461929603 |
| SIC Code | 8731 |
Key Executives
| Name | Position |
|---|---|
| Oliver R. Baumann | Chief Executive Officer and Executive Director |
| Carl von Halem | Chief Financial Officer |
| Beat Klaui | Head of Accounting and Taxation |
| Dr. Alexander Zink | Head of Technology and Innovation |
| Dr. Frank Ploger | Chief Scientific Officer |
| Dr. Dennis Fink | Senior Communications and Investor Relations Manager |
| Christian Faber | Chief Compliance Officer and Head of Legal and Compliance |